Literature DB >> 23448196

The need for better insulin therapy.

G Grunberger1.   

Abstract

Insulin replacement therapy corrects a core defect of diabetes pathophysiology. Since its introduction as a therapeutic modality almost 100 years ago, insulin therapy has undergone remarkable changes in purity and ability to provide more physiologic control of blood glucose levels. With glucose-lowering potential limited only by risks of hypoglycaemia, which remains the major limitation in our ability to achieve glycaemic goals, insulin replacement therapy remains a cornerstone of therapy. Major progress in reducing the risks of hypoglycemia has occurred with the development of insulin analogs. This review article briefly chronicles the evolution of insulin replacement strategies, highlighting both challenges in pharmaceutical development and patient acceptance, underscoring achievements, as well as denoting what improvements are still needed.
© 2013 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23448196     DOI: 10.1111/dom.12061

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  7 in total

Review 1.  Beyond traditional pharmacology: new tools and approaches.

Authors:  E V Gurevich; V V Gurevich
Journal:  Br J Pharmacol       Date:  2015-06-10       Impact factor: 8.739

Review 2.  Managing diabetes with nanomedicine: challenges and opportunities.

Authors:  Omid Veiseh; Benjamin C Tang; Kathryn A Whitehead; Daniel G Anderson; Robert Langer
Journal:  Nat Rev Drug Discov       Date:  2014-11-28       Impact factor: 84.694

3.  Clinical utility of insulin and insulin analogs.

Authors:  Ahter D Sanlioglu; Hasan Ali Altunbas; Mustafa Kemal Balci; Thomas S Griffith; Salih Sanlioglu
Journal:  Islets       Date:  2013-03-01       Impact factor: 2.694

Review 4.  Treatments for women with gestational diabetes mellitus: an overview of Cochrane systematic reviews.

Authors:  Ruth Martis; Caroline A Crowther; Emily Shepherd; Jane Alsweiler; Michelle R Downie; Julie Brown
Journal:  Cochrane Database Syst Rev       Date:  2018-08-14

5.  New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).

Authors:  G B Bolli; M C Riddle; R M Bergenstal; M Ziemen; K Sestakauskas; H Goyeau; P D Home
Journal:  Diabetes Obes Metab       Date:  2015-02-12       Impact factor: 6.577

Review 6.  Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes?

Authors:  P D Home
Journal:  Diabetes Obes Metab       Date:  2015-09-23       Impact factor: 6.577

7.  Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4).

Authors:  Philip D Home; Richard M Bergenstal; Geremia B Bolli; Monika Ziemen; Maria Rojeski; Melanie Espinasse; Matthew C Riddle
Journal:  Diabetes Obes Metab       Date:  2017-08-08       Impact factor: 6.577

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.